Ohio Mesothelioma Fact Sheet
While mesothelioma is a problem in all states, the specific incident rate for Ohio is 1.1 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in OH, recent OH mesothelioma-related court cases, mesothelioma specialists in OH and potential asbestos hotspots in Ohio.
[doptabs]
[doptab title=”Overview”]
Ohio Mesothelioma Info
By clicking on the above tabs, you will find information on mesothelioma specific to the state of Ohio
Ohio Research and Clinical Trials
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
Ohio Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
Ohio Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
[/doptab]
[doptab title=”Treatment and Research”]
Research
[dopaccordions]
[dopaccordion title=”Grever, Michael R. Southwest Oncology Group
Grant: 2U10CA004920-34″ icon=27 activeicon=28]
Abstract: This is a multi-disciplinary collaborative research project directed toward the development of more effective methods of prevention, detection, and treatment of human cancer in all its forms. Included in this project are the following programs: 1) the exploration of new therapeutic agents through a wide range of neoplastic diseases in Phase I, II and III studies, and the coincident study of the toxicities of these agents; 2) the exploration of new combinations of new and old agents in an effort to exploit synergistic combinations more effectively; 3) the development of multi-modal approaches to specific tumor problems using surgical, immunological and radiotherapeutic measures in optimal combinations; 4) the involvement of pertinent basis science disciplines such as biochemistry, pharmacology, cellular biology and mathematics in the formulation and execution of specific treatment protocols; 5) the improvement of cancer care in the community at large by using these programs in the educational effort directed at pre- and post- doctoral students, nurses, allied medical personnel and physicians, 6) the correlation and evaluation of biologic studies, and 7) the evaluation of cancer control efforts to as early detection mechanisms. This research effort will be conducted in cooperation with clinical and basic science investigators at other SWOG institutions and the NCI whose collective experience, information and wisdom will be used to design and conduct clinical trials which will answer important questions in the therapy of cancer. The Ohio State University has been a member and active participant in the Southwest Oncology Group for over thirty years. During this period OSU has grown to be the leading contributor in patient accrual for all SWOG institutions.
Tags: Combination Antineoplastic Therapy, Combination Chemotherapy, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Surgery Adenocarcinoma, Antineoplastic, Azacitidine, Bone Marrow Transplantation, Breast Neoplasm, Cancer Prevention, Cis Platinum Compound, Clinical Study /trial, Colony Stimulating Factor, Cooperative Study, Cyclophosphamide, Dacarbazine, Deoxycoformycin, Doxorubicin, Drug Adverse Effect, Drug Interaction, Etoposide, Fluorouracil, Gastrointestinal Neoplasm, Hairy T Cell Leukemia, Head /neck Neoplasm, Hepatoma, Human Therapy Evaluation, Ifosfamide, Immunomodulator, Interferon Alpha, Interleukin 1, Interleukin 2, Interleukin 3, Leukemia, Lung Neoplasm, Lymphokine Activated Killer Cell, Melanoma, Melphalan, Mesothelioma, Metastasis, Mitomycin C, Mitoxantrone, Multidrug Resistance, Multiple Myeloma, Nasopharyngeal Neoplasm, Neoplasm /cancer Diagnosis, Neoplasm /cancer Education, Neoplasm /cancer Relapse /recurrence, Ovary Neoplasm, Pancreas Neoplasm, Passive Immunization, Prognosis, Renal Cell Carcinoma, Sarcoma, Splenectomy, Taxol, Therapy Compliance, Tumor Necrosis Factor Alpha, Urinary Tract Neoplasm, Uterus Neoplasm Human Subject
- Followup Grant: 5U10CA004920-35
- Followup Grant: 5U10CA004920-36
- Followup Grant: 5U10CA004920-38
[/dopaccordion]
[dopaccordion title=”Skeel, Roland T. Eastern Cooperative Oncology Group Studies
Grant: 2U10CA039227-05″ icon=27 activeicon=28]
Abstract: The goal of this proposal is to improve knowledge of and treatment of cancer through participation of the Medical College of Ohio (MCO) with the Eastern Cooperative Oncology Group (ECOG). The method used will be to continue the successful amalgam of the scientific exPertise, organizational resources and outreach network of the Medical College with the patient resources and enthusiasm for clinical research in the Toledo community that has resulted in a broadly based cohesive clinical research group in Toledo. The success of the combined Toledo program is attested to by an annual accrual of over 155 patients onto ECOG studies, extensive multimodality scientific contributions to ECOG activities, leadership in ECOG committees and participation in group meetings. The core elements of MCO’s participation and this proposal are the scientific contributions by the radiotherapists, surgeons, and medical oncologists, particularly in gastrointestinal neoplasms, and the data management and quality control responsibility that the MCO maintains for the entire Toledo program, including those affiliates that are funded through the CCOP mechanism. The MCO will contribute to the scientific design and critique of clinical research in the ECOG through development of protocols for group- wide use; leadership and participation in disease oriented, modality, cancer control and health practices, and toxicity committees performance of pilot studies based upon local expertise and potential group-wide applicability; and timely publication of group studies. New therapeutic modalities, such as interstitial hyperthermia in conjunction with radiotherapy and chemotherapy, photodynamictherapy and intraoperative radiation therapy will continue to be developed and refined for integration into group- wide clinical trials. Developmental studies in chemoprevention of cancer will be brought to the ECOG through the Cancer Control and Health Practices Committee research on cancer prevention in high risk groups. The MCO will continue its active participation in ECOG group-wide trials and coordinate and monitor the quality of data from the entire Toledo Program. Through the design of scientifically sound ECOG studies based upon pre-clinical and early clinical trials at this institution and participation in group-wide studies, the MCO will continue to contribute to improvement in the care of patients with cancer.
Tags: Neoplasms Of Gastrointestinal System, Neoplastic Therapy, Cancer Radiotherapy, Neoplastic Therapy, Combination Antineoplastic Therapy, Therapy Evaluation, Human Antibiotics, Mitomycin, Drugs Adverse Effects, Folic Acid Antagonists, Methotrexate, Genetics, Cytogenetics, Halopyrimidines, Halouracil, Fluorouracil, Health Care Services, Case Finding And Outreach, Neoplasms Of Blood And Re System, Lymphoma, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Body Regions, Head And Neck, Neoplasms Of Gastrointestinal System, Esophagus Neoplasms, Neoplasms Of Gastrointestinal System, Rectum Growths, Neoplasms Of Pancreas, Neoplasms Of Reproductive System Female, Uterus Neoplasms, Cervix Neoplasms, Neoplasms Of Reproductive System, Breast Neoplasms, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplasms Of Skeletal System, Bone Neoplasms, Neoplasms Of Skin, Melanoma, Neoplasms Of Urinary Tract, Urinary Bladder Neoplasms, Neoplasms Prevention And Control, Neoplasms Surgery, Neoplasms, Sarcoma, Neoplastic Disease Epidemiology-statistics, Cancer Risk, Neoplastic Therapy, Cancer Chemotherapy, Neoplastic Therapy, Cancer Photoradiation Therapy, Neoplastic Therapy, Cancer Radioisotope (nuclear) Therapy, Neoplastic Therapy, Thermotherapy, Neoplastic Transformation, Carcinogenesis, Chemical, Proteins, Binding Proteins, Lectins Non-plant, Radiosensitizers, Cooperative Study Biomedical Systems Automated, Computer Assisted Patient Care, Cell Sorting, Laser, Human, Clinical, Nucleic Acid Hybridization, In Situ Hybridization, Radioisotopes, Iodine, Radioisotopes, Technetium
- Followup Grant: 5U10CA039227-06
- Followup Grant: 5U10CA039227-07
- Followup Grant: 5U10CA039227-08
- Followup Grant: 5U10CA039227-09
[/dopaccordion]
[dopaccordion title=”Skeel, Roland T. Cooperative Oncology Group
Grant: 3U10CA039227-09S1″ icon=27 activeicon=28]
Abstract: The goal of this proposal is to improve knowledge of and treatment of cancer through participation of the Medical College of Ohio (MCO) with the Eastern Cooperative Oncology Group (ECOG). The method used will be to continue the successful amalgam of the scientific exPertise, organizational resources and outreach network of the Medical College with the patient resources and enthusiasm for clinical research in the Toledo community that has resulted in a broadly based cohesive clinical research group in Toledo. The success of the combined Toledo program is attested to by an annual accrual of over 155 patients onto ECOG studies, extensive multimodality scientific contributions to ECOG activities, leadership in ECOG committees and participation in group meetings. The core elements of MCO’s participation and this proposal are the scientific contributions by the radiotherapists, surgeons, and medical oncologists, particularly in gastrointestinal neoplasms, and the data management and quality control responsibility that the MCO maintains for the entire Toledo program, including those affiliates that are funded through the CCOP mechanism. The MCO will contribute to the scientific design and critique of clinical research in the ECOG through development of protocols for group- wide use; leadership and participation in disease oriented, modality, cancer control and health practices, and toxicity committees performance of pilot studies based upon local expertise and potential group-wide applicability; and timely publication of group studies. New therapeutic modalities, such as interstitial hyperthermia in conjunction with radiotherapy and chemotherapy, photodynamictherapy and intraoperative radiation therapy will continue to be developed and refined for integration into group- wide clinical trials. Developmental studies in chemoprevention of cancer will be brought to the ECOG through the Cancer Control and Health Practices Committee research on cancer prevention in high risk groups. The MCO will continue its active participation in ECOG group-wide trials and coordinate and monitor the quality of data from the entire Toledo Program. Through the design of scientifically sound ECOG studies based upon pre-clinical and early clinical trials at this institution and participation in group-wide studies, the MCO will continue to contribute to improvement in the care of patients with cancer.
Tags: Chemoprevention, Combination Antineoplastic Therapy, Gastrointestinal Neoplasm, Human Therapy Evaluation, Neoplasm /cancer Radiation Therapy Bladder Neoplasm, Bone Neoplasm, Breast Neoplasm, Cancer Prevention, Cancer Risk, Cervix Neoplasm, Chemical Carcinogenesis, Clinical Trial, Cooperative Study, Cytogenetics, Drug Adverse Effect, Esophagus Neoplasm, Fluorouracil, Head /neck Neoplasm, Lectin, Lung Neoplasm, Lymphoma, Medical Outreach /case Finding, Melanoma, Mesothelioma, Methotrexate, Mitomycin, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Photoradiation Therapy, Neoplasm /cancer Radionuclide Therapy, Neoplasm /cancer Surgery, Neoplasm /cancer Thermotherapy, Pancreas Neoplasm, Radiosensitizer, Rectum Neoplasm, Sarcoma Computer Assisted Patient Care, Flow Cytometry, Human Subject, In Situ Hybridization, Iodine, Radionuclide, Technetium
[/dopaccordion]
[/dopaccordions]
Clinical Trials
[dopaccordions]
[dopaccordion title=”Active, not recruiting Pazopanib in Treating Patients With Malignant Pleural Mesothelioma” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
More Information
[/dopaccordion]
[dopaccordion title=”Completed Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: erlotinib hydrochloride
More Information
[/dopaccordion]
[dopaccordion title=”Active, not recruiting AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate
More Information
[/dopaccordion]
[dopaccordion title=”Active, not recruiting Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information
[/dopaccordion]
[dopaccordion title=”Suspended Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: everolimus
More Information
[/dopaccordion]
[dopaccordion title=”Active, not recruiting Pemetrexed Disodium and Either Gemcitabine or Carboplatin in Treating Patients With Advanced Malignant Pleural Mesothelioma” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information
[/dopaccordion]
[dopaccordion title=”Completed Gefitinib in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: gefitinib
More Information
[/dopaccordion]
[dopaccordion title=”Active, not recruiting Capecitabine in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
More Information
[/dopaccordion]
[dopaccordion title=”Active, not recruiting Sorafenib in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: sorafenib tosylate
More Information
[/dopaccordion]
[dopaccordion title=”Active, not recruiting PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: vatalanib
More Information
[/dopaccordion]
[dopaccordion title=”Active, not recruiting Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
More Information
[/dopaccordion]
[dopaccordion title=”Recruiting Optical Coherence Tomography of the Airway in Detecting Abnormal Cells in Patients Undergoing Surgery for Lung Cancer or Lung Disease” icon=27 activeicon=28]
Condition: Lung Cancer; Malignant Mesothelioma; Metastatic Cancer; Precancerous/Nonmalignant Condition
Intervention: Procedure: bronchoscopic and lung imaging studies; Procedure: diagnostic bronchoscopy; Procedure: histopathologic examination; Procedure: optical coherence tomography
More Information
[/dopaccordion]
[dopaccordion title=”Completed Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: pemetrexed disodium
More Information
[/dopaccordion]
[dopaccordion title=”Active, not recruiting Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: methotrexate; Drug: vinorelbine ditartrate; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
More Information
[/dopaccordion]
[dopaccordion title=”Completed Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride
More Information
[/dopaccordion]
[dopaccordion title=”Active, not recruiting Pemetrexed Disodium and Gemcitabine in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]
Condition: Malignant Mesothelioma
Intervention: Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information
[/dopaccordion]
[dopaccordion title=”Completed Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma” icon=27 activeicon=28]
Condition: Mesothelioma
Intervention: Drug: Pemetrexed; Drug: Gemcitabine
More Information
[/dopaccordion]
[dopaccordion title=”Completed Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction” icon=27 activeicon=28]
Condition: Cancer
Intervention: Drug: erlotinib hydrochloride
More Information
[/dopaccordion]
[dopaccordion title=”Recruiting Collecting Tumor Samples From Patients With Gynecological Tumors” icon=27 activeicon=28]
Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information
[/dopaccordion]
[/dopaccordions]
[/doptab]
[doptab title=”Doctors and Hospital”]
Hospitals and Cancer Centers
We do not have any doctors or cancer centers for this state at the moment.
[/doptab]
[doptab title=”Cases”]
DiCenzo v. A Best Prods. Co.
No. 2007-1628, SUPREME COURT OF OHIO, June 4, 2008, Submitted, October 22, 2008, Decided
State ex rel. Pilkington N. Am., Inc. v. Indus. Comm’n
No. 2007-0747, SUPREME COURT OF OHIO, February 26, 2008, Submitted, April 3, 2008, Decided
State ex rel. Hiatt v. Indus. Comm’n
No. 2002-1116 , SUPREME COURT OF OHIO, April 15, 2003, Submitted , May 16, 2003, Decided
State ex rel. Maynard v. Indus. Comm’n
No. 2001-1386 , SUPREME COURT OF OHIO, October 15, 2002, Submitted , December 4, 2002, Decided
State ex rel. Hubbard v. Indus. Comm’n of Ohio
No. 2001-0201, SUPREME COURT OF OHIO, June 4, 2002, Submitted , September 25, 2002, Decided
State ex rel. Liposchak v. Industrial Comm’n
No. 98-2287, SUPREME COURT OF OHIO, June 6, 2000, Submitted , November 15, 2000, Decided
State ex rel. Thompson v. Ohio Edison Co.
No. 96-1715, SUPREME COURT OF OHIO, January 12, 1999, Submitted , April 7, 1999, Decided
Werts v. Goodyear Tire & Rubber Co.
No. 9 1403, COURT OF APPEALS OF OHIO, EIGHTH APPELLATE DISTRICT, CUYAHOGA COUNTY, June 4, 2009, Released
Fagerholm v. GE
No. 91986, COURT OF APPEALS OF OHIO, EIGHTH APPELLATE DISTRICT, CUYAHOGA COUNTY, May 21, 2009, Released
Oglesby v. CONRAIL Corp.
Court Of Appeals No. E-08-055, COURT OF APPEALS OF OHIO, SIXTH APPELLATE DISTRICT, ERIE COUNTY, March 31, 2009, Decided
[/doptab]
[doptab title=”Lawyers”]
If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:
[/doptab]
[/doptabs]